Showing results (201-210 of 228) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
The New England Journal of Medicine|January 24, 2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemiaRichard R Furman, Jeff P Sharman, Steven E Coutre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The New England Journal of Medicine|December 8, 2015
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C Byrd, Bonnie Harrington, Susan O'Brien, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
Pageof 23